Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.5400
- TODAY'S CHANGE (%)0.3100 (5.9273%)
- Bid / Lots5.5300/ 2
- Ask / Lots5.5500/ 4
- Open / Previous Close5.2600 / 5.2300
- Day Range
- 52 Week Range
- Volume399,406
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 4932 | 5.26 |
| 09:34 ET | 2990 | 5.3 |
| 09:36 ET | 612 | 5.36 |
| 09:38 ET | 593 | 5.31 |
| 09:39 ET | 9563 | 5.3 |
| 09:45 ET | 300 | 5.29 |
| 09:48 ET | 2700 | 5.295 |
| 09:52 ET | 1111 | 5.28 |
| 09:54 ET | 500 | 5.26 |
| 09:56 ET | 300 | 5.25 |
| 09:57 ET | 100 | 5.25 |
| 09:59 ET | 1846 | 5.245 |
| 10:01 ET | 200 | 5.28 |
| 10:03 ET | 2897 | 5.37 |
| 10:08 ET | 14213 | 5.48 |
| 10:10 ET | 21762 | 5.5 |
| 10:12 ET | 1800 | 5.46 |
| 10:14 ET | 52967 | 5.47 |
| 10:15 ET | 100 | 5.48 |
| 10:17 ET | 5300 | 5.475 |
| 10:19 ET | 10856 | 5.5 |
| 10:21 ET | 3005 | 5.58 |
| 10:24 ET | 5260 | 5.62 |
| 10:26 ET | 5626 | 5.689 |
| 10:28 ET | 3037 | 5.51 |
| 10:30 ET | 2106 | 5.56 |
| 10:32 ET | 1549 | 5.54 |
| 10:33 ET | 2705 | 5.51 |
| 10:35 ET | 883 | 5.52 |
| 10:37 ET | 17152 | 5.45 |
| 10:39 ET | 712 | 5.485 |
| 10:42 ET | 325 | 5.4701 |
| 10:44 ET | 10654 | 5.49 |
| 10:46 ET | 1300 | 5.49 |
| 10:48 ET | 1750 | 5.48 |
| 10:50 ET | 1125 | 5.48 |
| 10:51 ET | 100 | 5.47 |
| 10:53 ET | 11839 | 5.45 |
| 10:55 ET | 12508 | 5.43 |
| 10:57 ET | 6000 | 5.45 |
| 11:00 ET | 200 | 5.46 |
| 11:08 ET | 2471 | 5.48 |
| 11:15 ET | 400 | 5.48 |
| 11:18 ET | 918 | 5.5 |
| 11:20 ET | 2080 | 5.495 |
| 11:22 ET | 100 | 5.51 |
| 11:24 ET | 200 | 5.52 |
| 11:27 ET | 100 | 5.52 |
| 11:29 ET | 400 | 5.5 |
| 11:31 ET | 400 | 5.51 |
| 11:33 ET | 600 | 5.5 |
| 11:36 ET | 881 | 5.51 |
| 11:38 ET | 100 | 5.505 |
| 11:40 ET | 4896 | 5.51 |
| 11:42 ET | 100 | 5.49 |
| 11:44 ET | 1300 | 5.53 |
| 11:45 ET | 260 | 5.51 |
| 11:47 ET | 873 | 5.465 |
| 11:49 ET | 1267 | 5.485 |
| 11:51 ET | 100 | 5.48 |
| 11:54 ET | 3283 | 5.485 |
| 12:00 ET | 300 | 5.47 |
| 12:03 ET | 300 | 5.48 |
| 12:05 ET | 100 | 5.46 |
| 12:07 ET | 650 | 5.48 |
| 12:09 ET | 508 | 5.52 |
| 12:12 ET | 1900 | 5.51 |
| 12:14 ET | 500 | 5.52 |
| 12:16 ET | 364 | 5.5 |
| 12:20 ET | 200 | 5.51 |
| 12:21 ET | 5800 | 5.49 |
| 12:25 ET | 100 | 5.52 |
| 12:30 ET | 470 | 5.5 |
| 12:32 ET | 455 | 5.49 |
| 12:34 ET | 1000 | 5.51 |
| 12:38 ET | 1300 | 5.52 |
| 12:39 ET | 500 | 5.52 |
| 12:43 ET | 800 | 5.52 |
| 12:45 ET | 446 | 5.5 |
| 12:48 ET | 1041 | 5.48 |
| 12:50 ET | 590 | 5.5 |
| 12:54 ET | 600 | 5.5 |
| 12:57 ET | 1133 | 5.5 |
| 12:59 ET | 1253 | 5.54 |
| 01:03 ET | 3586 | 5.53 |
| 01:10 ET | 200 | 5.54 |
| 01:14 ET | 972 | 5.52 |
| 01:15 ET | 700 | 5.5 |
| 01:19 ET | 734 | 5.51 |
| 01:21 ET | 1241 | 5.51 |
| 01:24 ET | 200 | 5.5 |
| 01:30 ET | 6323 | 5.52 |
| 01:32 ET | 1100 | 5.52 |
| 01:33 ET | 305 | 5.52 |
| 01:35 ET | 904 | 5.52 |
| 01:37 ET | 863 | 5.51 |
| 01:39 ET | 486 | 5.53 |
| 01:42 ET | 300 | 5.53 |
| 01:46 ET | 100 | 5.53 |
| 01:50 ET | 2989 | 5.56 |
| 01:53 ET | 200 | 5.55 |
| 01:57 ET | 100 | 5.55 |
| 02:00 ET | 9674 | 5.54 |
| 02:02 ET | 100 | 5.54 |
| 02:04 ET | 785 | 5.54 |
| 02:09 ET | 100 | 5.54 |
| 02:13 ET | 2098 | 5.54 |
| 02:15 ET | 1982 | 5.53 |
| 02:18 ET | 842 | 5.53 |
| 02:24 ET | 1322 | 5.53 |
| 02:26 ET | 1779 | 5.55 |
| 02:29 ET | 300 | 5.558 |
| 02:31 ET | 400 | 5.54 |
| 02:36 ET | 596 | 5.53 |
| 02:38 ET | 100 | 5.53 |
| 02:40 ET | 1400 | 5.53 |
| 02:42 ET | 6300 | 5.5 |
| 02:45 ET | 2394 | 5.5 |
| 02:47 ET | 500 | 5.5 |
| 02:51 ET | 200 | 5.51 |
| 02:54 ET | 100 | 5.51 |
| 02:56 ET | 2963 | 5.47 |
| 02:58 ET | 850 | 5.49 |
| 03:00 ET | 1190 | 5.495 |
| 03:02 ET | 600 | 5.5099 |
| 03:05 ET | 1099 | 5.48 |
| 03:09 ET | 1100 | 5.475 |
| 03:12 ET | 2450 | 5.48 |
| 03:14 ET | 1009 | 5.5 |
| 03:16 ET | 500 | 5.5 |
| 03:21 ET | 3111 | 5.53 |
| 03:23 ET | 200 | 5.5228 |
| 03:25 ET | 700 | 5.55 |
| 03:27 ET | 100 | 5.54 |
Aug 9, 2024
DJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:14AM ET on Friday Aug 09, 2024 by Dow Jones
6:14AM ET on Friday Aug 09, 2024 by Dow Jones
Aug 8, 2024
DJ Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment, from 8:24AM ET on Thursday Aug 08, 2024 by Dow Jones
8:24AM ET on Thursday Aug 08, 2024 by Dow JonesAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap, from 7:00AM ET on Thursday Aug 08, 2024 by Dow Jones
7:00AM ET on Thursday Aug 08, 2024 by Dow Jones
Aug 7, 2024
Aug 2, 2024
DJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 8:25AM ET on Friday Aug 02, 2024 by Dow Jones
8:25AM ET on Friday Aug 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 310.8M | -8.7x | --- |
Prelude Therapeutics Inc | 307.6M | -3.0x | --- |
PepGen Inc | 314.8M | -2.9x | --- |
Atea Pharmaceuticals Inc | 319.1M | -1.9x | --- |
Nautilus Biotechnology Inc | 301.0M | -4.7x | --- |
Inozyme Pharma Inc | 320.6M | -3.8x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $310.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
